Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control

Archives of Endocrinology and Metabolism

Volumn 61, Issue 2, 2017, Pages 188-192

  Villar, Miriam Méndez del ^a   Martínez Abundis, Esperanza ^a   Preciado Márquez, Rafael O ^a   González Ortiz, Manuel ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Diacerein; Glycemic control; Metformin; Type 2 diabetes mellitus

Indexed keywords

ANTHRAQUINONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; DIACEREIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PLACEBO;

ADULT; ANALYSIS; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; NONPARAMETRIC TEST; OBESITY; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; OVERWEIGHT; PLACEBOS; POSTPRANDIAL PERIOD; REPRODUCIBILITY OF RESULTS; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 85018826024     PISSN: 23593997     EISSN: 23594292     Source Type: Journal    
DOI: 10.1590/2359-3997000000242     Document Type: Article

References (16)

1. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 2006;83:461S-5S.
2. Kang YE, Kim JM, Joung KH, Lee JH, You BR, Choi MJ, et al. The Roles of Adipokines, Proinflammatory Cytokines, and Adipose Tissue Macrophages in Obesity-Associated Insulin Resistance in Modest Obesity and Early Metabolic Dysfunction. PLos One. 2016;11:e0154003.
3. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb. 2010;17:332-41.
4. Donath MY, Størling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev. 2008;29:334-50.
5. Pavelka K, Bruyère O, Cooper C, Kanis JA, Leeb BF, Maheu E, et al. Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging. 2016;33:75-85.
6. McCreight LJ, Bailey CJ, Pearson ER. Metformin and gastrointestinal tract. Diabetologia. 2016;59:426-35.
7. Malaguti C, Vilella CA, Vieira KP, Souza GH, Hyslop S, Zollner Rde L. Diacerhein downregulates proinflammatory cytokines expression and decreases the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. Int Immunopharmacol. 2008;8:782-91.
8. Tobar N, Oliveira AG, Guadagnini D, Bagarolli RA, Rocha GZ, Araújo TG, et al. Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology. 2011;152: 4080-93.
9. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56:1898-906.
10. Ramos-Zavala MG, González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, González-López R, Santiago-Hernández NJ. Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care. 2011;34:1591-4.
11. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-9.
12. Kalra S, Gupta Y. Oral combination therapy in primary care. J Park Med Assoc. 2015;65:574-5.
13. Jeyaseelan L, Rao PSS. Methods of determining sample sizes in clinical trials. Indian J Pediatr. 1989,26:115-21.
14. Ortis F, Pirot P, Naamane N, Kreins AY, Rasschaert J, Moore F, et al. Induction of nuclear factor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells. Diabetologia. 2008;51:1213-25.
15. Martínez-Abundis E, Reynoso-von Drateln C, Hernández-Salazar E, González-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res. 2007;299:461-5.
16. González-Ortiz M, Pascoe-González S, Esperanzamartínez-Abundis, Kam-Ramos AM, Hernández-Salazar E. Effect of celecoxib, a cyclooxygenase-2-specific inhibitor, on insulin sensitivity, C-reactive protein, homocysteine, and metabolic profile in over-weight or obese subjects. Metab Syndr Relat Disord. 2005;3:95-101.